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INTRODUCTION
Staphylococcus aureus is a major human pathogen responsible for 
a wide variety of ocular diseases, including sight-threatening infec-
tions(1-4). Since the first report of a new strain of S. aureus, the so-called 
methicillin-resistant Staphylococcus aureus (MRSA), its prevalence and 
morbidity has been increasing worldwide. Moreover, the antibiotic 
ABSTRACT
Purpose: To study the prevalence of methicillin-resistant Staphylococcus aureus 
among S. aureus ocular infections in a tertiary health center in Brazil and compare 
antibiotic susceptibility patterns between MRSA and methicillin-susceptible S. 
aureus isolates.
Methods: Electronic records from the ocular microbiology laboratory of the 
Universidade Federal de São Paulo were retrospectively reviewed. During a 
10-year period (between January 2000 and December 2009) all conjunctivitis, 
keratitis, and endophthalmitis cases with a positive culture for S. aureus were 
identified. Antibiotic susceptibility was determined using the Kirby-Bauer disk 
diffusion method. 
Results: Five hundred sixty-six S. aureus isolates were identified; of those, 56 
(9.9%) were resistant to methicillin. Throughout the 10-year period, Staphylococcus 
aureus showed a significant increasing trend from 7.55% to 16.18% among overall 
S. aurues infections (p=0.001) and from 3.7% to 13.16% in conjunctivitis (p=0.001). 
Conversely, we did not observe the same trend among those with keratitis (p=0.38). 
Staphylococcus aureus isolates showed higher resistance rates to tobramycin, 
gentamicin, ciprofloxacin, gatifloxacin, and moxifloxacin when compared with S. 
aureus isolates (p< 0.001). All cases were susceptible to vancomycin. 
Conclusion: We observed an increasing trend in the overall prevalence of 
Staphylococcus aureus ocular infections and statistically significant higher 
resistance rates to commonly used antibiotics compared to Staphylococcus 
aureus. Our data supports the need for constant bacterial surveillance and 
should be taken into consideration before initiating empiric treatment of 
ocular infections. 
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RESUMO
Objetivo: Estudar a prevalência do Staphylococcus aureus resistente à meticilina nas 
infecções oculares causadas por S. aureus em um centro de saúde terciário no Brasil e 
comparar o perfil de suscetibilidade antimicrobiana entre as cepas de Staphylococcus 
aureus resistente à meticilina e S. aureus susceptível à meticilina 
Métodos: Foi realizada uma análise retrospectiva dos arquivos do laboratório de mi­
crobiologia ocular da Universidade Federal de São Paulo e selecionados todos os casos 
de conjuntivite, ceratite e endoftalmite com cultivo positivo para S. aureus, durante um 
período de 10 anos (entre janeiro de 2000 e dezembro de 2009). Foi avaliada a prevalência 
de Staphylococcus aureus resistente à meticilina e comparado o perfil de susceptibilidade 
antimicrobiano dos Staphylococcus aureus resistente à meticilina e S. aureus susceptível 
à meticilina.
Resultados: Quinhentos e sessenta e seis isolados de S. aureus foram identificados. 
Desses, 56 (9,9%) apresentaram resistência à meticilina. Durante o período de 10 anos 
estudado, Staphylococcus aureus resistente à meticilina mostrou uma tendência sig­
nificante de aumento de 7,6% para 16,2% entre as infecções oculares causadas por S. 
aureus em geral (p=0,001) e de 3,7% para 13,2% nas conjuntivites (p=0,001). A mesma 
tendência não foi observada entre as amostras de ceratite (p=0,38). Os isolados de Sta-
phylococcus aureus resistente à meticilina mostraram maiores taxas de resistência à 
tobramicina, gentamicina, ciprofloxacino, gatifloxacino e moxifloxacino em comparação 
com os isolados de S. aureus susceptível à meticilina (p<0,001). Todos os casos foram 
susceptíveis à vancomicina. 
Conclusão: Foi observada uma tendência de aumento na prevalência do Staphylo-
coccus aureus resistente à meticilina nas infecções oculares causadas por S. aureus, 
bem como taxas de resistência significantemente maiores aos antibióticos comumente 
utilizados na prática oftalmológica. Nossos dados alertam para a necessidade de cons­
tante vigilância de resistência bacteriana a antimicrobianos e devem ser considerados 
na eleição do tratamento empírico das infecções oculares. 
Descritores: Conjuntivites; Ceratites; Endoftalmites; Staphylococcus aureus resistente 
à meticilina; Fluoroquinolonas
susceptibility is decreasing, introducing new challenges regarding 
its treatment and making constant antibiotic surveillance a priority.
The mechanism of resistance to semisynthetic penicillins, inclu-
ding oxacillin and methicillin, is based on structural changes of its 
target site. MRSA has also developed resistance to this compound as 
well as all β-lactam agents by acquiring the mecA gene, which is car-
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ried on a large mobile genetic element called staphylococcal cassette 
chromosome mec (SCCmec). The mecA gene encodes for an alternati-
ve penicillin-binding protein: PBP2a, that has low affinity for β-lactam 
and allows MRSA strains to survive in different concentrations of 
these antimicrobial agents(5). As a consequence, the treatment of 
MRSA infections has been restricted to selected antibiotics, usually 
glycopeptides. Furthermore, due to the high capability to develop 
resistance, MRSA strains with reduced susceptibility to vancomycin 
have been isolated(6). 
It is known that MRSA prevalence and antimicrobial suscep-
tibility patterns have substantial geographical variation(7). In the 
United States, the results from the Antibiotic Resistance Monitoring 
in Ocular Microorganisms (ARMOR) study showed a prevalence of 
39% of MRSA among all S. aureus ocular isolates and a considerable 
increase in the resistance rates to fluoroquinolones(8). Other studies 
conducted in developing countries showed similar resistance pat-
terns and even higher prevalence rates that ranged from 34% to 
53%(9,10). Although these previous studies are important to guide the 
treatment of ocular infections, their results may not reflect the current 
prevalence of MRSA in other geographic areas. Therefore, the study of 
the prevalence and susceptibility of MRSA in Latin America is of major 
importance in the management of ocular infections. 
The purpose of our study was to evaluate the prevalence of MRSA 
among S. aureus ocular infections in a tertiary health center in Brazil 
and compare antibiotic susceptibility patterns between MRSA and 
methicillin-susceptible S. aureus (MSSA) isolates. 
METHODS
This was a retrospective study conducted at the Universidade Fede-
ral de São Paulo (UNIFESP), from January 2000 to December 2009. The 
Ocular Microbiology Laboratory receives specimens from emergency 
services and outpatient clinics referred to the São Paulo Hospital, a 
tertiary health center in São Paulo, Brazil. For this study isolates were de- 
identified in order to protect patient identity. Then, we reviewed elec-
tronic records from the ocular microbiology laboratory and identified 
all conjunctivitis, keratitis, and endophthalmitis cases with a positive 
culture for S. aureus. If records showed more than one diagnosis, the pri-
mary pathology or the more severe diagnosis was chosen. Consecutive 
and non-duplicate S. aureus isolates were included in the final analysis. 
Cultures were obtained from conjunctival swabs, corneal scrapings, 
surgically removed stitches, aqueous humor, vitreous, and surgically 
removed intraocular lenses. The Universidade Federal de São Paulo Ethi-
cal Committee approved the protocol (protocol number: 72618) and 
methods described adhered to the tenets of the Declaration of Helsinki. 
As a routine in our service, Staphylococcus species were iden-
tified by standard biochemical tests including catalase, coagulase, 
and DNase tests. Antibiotic susceptibility was determined using the 
 Kirby- Bauer disk diffusion method. Results were interpreted accor-
ding to the latest Clinical Laboratory Standards Institute (CLSI) gui-
delines available at the time of the antibiotic susceptibility testing(11). 
For the purpose of this study, isolates were considered resistant to 
methicillin if resistance to either oxacillin or cefoxitin was identified. 
Prevalence of MRSA among S. aureus isolates was calculated on an 
annual basis for each diagnostic category (conjunctivitis, keratitis, and 
endophthalmitis) and for the overall number of cases (sum of the total 
number of cases). We also recorded the susceptibility to tobramycin, 
gentamicin, ciprofloxacin, gatifloxacin, moxifloxacin, and vancomycin 
of each of the strains and compared their rates between MRSA and 
MSSA isolates. Proportions were tested with the Fisher exact test and 
a trend test was performed to investigate changes in prevalence rates 
yearly. All statistical analyses were performed with commercially availa-
ble software (Stata version 10, StataCorp, College Station, TX). P-values 
less than 0.05 were considered statistically significant.
RESULTS
We included in our study 566 S. aureus isolates identified from Ja-
nuary 2000 to December 2009. Fifty-six isolates (9.9%) were resistant 
to methicillin. The median age of included subjects was 35.8 years 
(range from 6 days to 98 years). Patients with positive MRSA samples 
were significantly younger than patients with MSSA samples (median 
age of 27.9 vs. 36.7, respectively, p=0.014). No difference in sex was 
found between groups. 
Table 1 shows the number of MRSA cases per year according to 
diagnostic category. Throughout the 10-year period, MRSA showed 
a significant increasing trend from 7.55 to 16.18% among overall S. 
aureus infections (p=0.001) and from 3.7 to 13.16% in conjunctivitis 
(p=0.001). Conversely, we did not observe the same trend among 
those with keratitis (p=0.38). The small number of endophthalmitis 
did not allow us to make statistical inferences.
MRSA was more prevalent in endophthalmitis cases than in con-
junctivitis (21.4 vs. 10.0%, respectively, p<0.001) or keratitis cases (21.4 
vs. 8.4%, respectively, p<0.001). Besides, MRSA was more prevalent in 
endophthalmitis cases than in the sum of conjunctivitis and keratitis 
cases (21.4 vs. 9.3%, respectively, p=0.036). 
Figure 1 illustrates the antibiotic susceptibility rates of MRSA and 
MSSA isolates. Fifty-six point four percent (56.4%) of MRSA strains 
were susceptible to tobramycin, 70% to gentamicin, 62% to cipro-
floxacin, 88.4% to gatifloxacin, and 85.1% to moxifloxacin. For MSSA 
Table 1. Annual prevalence of methicillin-resistant S. aureus (MRSA) and total S. aureus (SA) ocular infections according to diagnostic category
  Conjunctivitis Keratitis Endophthalmitis Overall
Year MRSA Total SA MRSA Total SA MRSA Total SA MRSA Total SA
2000 01 (03.7%) 27 03 (12.0%) 025 0 01 04 (07.6%) 053
2001 02 (05.3%) 38 01 (03.9%) 026 0 07 03 (04.2%) 071
2002 0 32 01 (04.4%) 023 0 01 01 (01.8%) 056
2003 01 (02.9%) 34 0 014 1 (50.0%) 02 02 (04.0%) 050
2004 01 (03.0%) 33 02 (10.0%) 020 1 (50.0%) 02 04 (07.3%) 055
2005 08 (27.6%) 29 02 (10.0%) 020 0 02 10 (19.6%) 051
2006 01 (05.6%) 18 01 (06.3%) 016 0 05 02 (05.1%) 039
2007 07 (21.2%) 33 04 (09.1%) 044 1 (33.3%) 03 12 (15.0%) 080
2008 04 (23.5%) 17 03 (11.5%) 026 0 00 07 (16.3%) 043
2009 05 (13.2%) 38 03 (12.0%) 025 3 (60.0%) 05 11 (16.2%) 068
Total 30 (10.0%) 299 20 (08.4%) 239 6 (21.4%) 28 56 (09.9%) 566
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isolates, susceptibility rates for the same antibiotics were 86.8, 92.6, 
96, 99.7, and 100%, respectively. MRSA isolates were statistically more 
resistant to all mentioned antibiotics than MSSA isolates (p<0.001 for 
all comparisons). All isolates were susceptible to vancomycin. 
DISCUSSION
Our study showed the prevalence of MRSA ocular infections over 
a 10-year period in Brazil. To the best of our knowledge, this is the 
largest reported case series of ocular infections related to MRSA in 
South America. These findings must be taken into consideration for 
effective prevention and treatment strategies. 
Previous studies have evaluated the prevalence of MRSA among 
ocular infections in the United States(8,12-16). In India, Bagga et al. repor-
ted a prevalence of MRSA of 43%, which is similar to the prevalence 
reported in studies from the United States(9). Another recent study 
performed in China that included 519 ocular infections positive to 
S. aureus, reported an even higher prevalence of 52.8% of MRSA(10). 
However, in Europe Morrissey et al. showed that 22% of the S. aureus 
ocular infections were caused by MRSA(17). The 9.9% prevalence of 
MRSA reported in our study is considerably lower than the prevalence 
reported by previous studies in other countries; it is also lower than 
other studies performed in Brazilian general hospitals(18,19). This may 
reflect real differences in the prevalence of MRSA, the standards of 
microbiology tests, or even epidemiological changes over time. 
Our results support previous evidences of MRSA lower antibiotic 
susceptibility rates, compared to MSSA. However, compared with the 
international literature our susceptibility rates were higher(9,13-17). In our 
study the susceptibility rates for fourth-generation fluoroquinolones 
(gatifloxacin and moxifloxacin) were 88% and 85%, respectively, com -
pared with 18% and 24% in the Ocular Tracking Resistance in U.S. Today 
group (TRUST)(12). Therefore, the use of fourth-generation fluoroqui-
nolones for empiric treatment is still a good option in our region. In 
contrast, the percentage of MRSA strains susceptible to tobramycin 
and gentamicin in our study was only 56.4% and 70%, respectively. 
The percentage of MRSA among endophthalmitis cases was found 
to be significantly higher than the sum of conjunctivitis and keratitis ca-
ses (21.4 vs. 9.3%, respectively, p=0.036). This can be partially explained 
by the fact that MRSA prevalence might be affected by the previous 
use of antibiotics(20-23). In our study endophthalmitis cases were fre-
quently associated with surgery, and the prophylactic regimens used in 
the perioperative period could cause the selection of resistant strains. 
Further investigations are necessary to confirm and explain this finding.
It is important to highlight that in vitro bacterial susceptibility 
patterns are not fully equivalent to in vivo susceptibility. Many va-
riables exist in this equation including factors depending on the 
antimicrobial pharmacokinetics (PK) and pharmacodynamics (PD), 
microorganism, site of infection, and host. Moreover, it can be diffi-
cult to establish breakpoints in susceptibility tests regarding ocular 
infections. Although the CLSI recommends breakpoints based on PK/
PD index and microbiological data, those values may not represent 
the concentrations expected in ocular applications. In addition, it is 
known that antibiotic concentrations differ according to the form of 
drug delivery. For example, topical antibiotics are associated with higher 
concentrations of the drug in the ocular surface and cornea, and 
intravitreal injection directly increases the amount of drug available 
in the vitreous. It is also important to remember that different com-
ponents might change the drug efficacy. Benzalkonium chloride, for 
instance, is a bacteriostatic and bactericidal agent used as preservati-
ve in many marketed formulations including fluoroquinolones. It has 
been demonstrated that gatifloxacin formulated with benzalkonium 
chloride has better antimicrobial effect than gatifloxacin alone, with 
a significant reduction in gatifloxacin minimum inhibitory concentra-
tion (MIC) against different ocular pathogens(24).
Direct implication of methicillin resistance on prognosis of ocu-
lar infections is still unclear. Although it is obviously influenced by 
the delay in the introduction of the appropriate antibiotic regimen, 
virulence factors are also a major concern. Virulence factors are res-
ponsible for the capability of the bacteria to cause disease and are 
correlated with the severity of the disease. Interestingly, the associa-
tion between increased antibiotic resistance and decreased virulence 
has already been described for S. aureus(25). Moreover, MRSA showed 
increased mortality rates compared with MSSA in several studies(26-29). 
However, little is known about the prognosis associated with MRSA 
ocular infections. Major et al. evaluated 32 patients with endophthal-
mitis and reported that the visual acuity after MRSA and MSSA 
endophthalmitis was similar(14). Since our study had a cross-sectional 
design, we were unable to make conclusions about prognosis. Future 
studies should investigate the real implications and management of 
MRSA in ocular infections.
In conclusion, our study revealed an increasing trend in the ove-
rall prevalence of MRSA ocular infections compared to MSSA. Our 
re sults also support previous evidence of an association between 
resistance to methicillin and resistance to non β-lactam antibiotics, 
including fluoroquinolones. These findings should be taken in consi-
deration before initiating empiric treatment of ocular infections and 
illustrates the need for constant bacterial surveillance.
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